Table 2.

Details on Stroke Evaluation and Treatment

Study	National Institutes of Health Stroke Scale score, median (IQR)		Onset to intravenous thrombolysis (min) median (IQR)		Any antiplatelets (%)		Alteplase (%)		Tenecteplase (%)		Endovascular therapy (%)
	AC	CTRL	AC	CTRL	AC	CTRL	AC	CTRL	AC	CTRL	AC	CTRL
Seiffge et al 2017 22 , 23	13 (7–19)		37 (30–60)*		16.6		100		0		0
Meinel et al 2023 32 †	11 (6–17)	9 (5–16)	153 (110–210)	138 (98–190)	10.6	32	93.9	96.2	6.1	3.8	34.2	18.8
Kam et al 2022 33	10 (5–17)	7 (4–14)	122 (89–168)	123 (91–168)	34.8	45.6	100	100	0	0	18.8	11.5
Okada et al 2022 34	15 (5–24)	9 (4–17)	148 (103–190)	122 (90–173)	17.5	27.3	100	100	0	0	40	25.7
Frol et al 2021 35	10.5 (18)	8 (27)	140 (−)‡	…	…	…	100	100	0	0	0	0
Xian et al 201736 §	12 (6–18)	9 (5–15)	…	…	30.3	47.8	100	100	0	0	…	…
Beharry et al 2020 37	6 (4–21)	…	7.7	0	100	38.4
Fang et al 2019 38	14 (12–23)	11.1 (4.9)ǁ , ‡	…	100	0	10
Kikule et al 2022 39	9 (6–16)		…		…		100		0		0
Kermer et al 2020 40	9 (−)		…		…		100		0		7.5
Šaňák et al 2018 41	7 (3–24)		22 (18)§ , ‡		…		100		0		7.7
Tse et al 2017 42	21 (6–22)		211.5 (185–220)		…		100		0		16.6
Suzuki et al 2017 43	13 (8–18)¶, 21 (18–27)#		159 (48)¶ , #, 148 (51)# , ‡		2.8		100		0		21.2
Shahjouei et al 2015 44	10 (2–15)		115 (29)‡		…		100		0		0

AC indicates anticoagulation group; CTRL, control group; IQR, interquartile range; and tPA, tissue plasminogen activator.

^*Door to needle time.

^† Tenecteplase 0.25 mg/kg was given to 51 and 1225 patients of the AC and CTRL groups, respectively.

^‡ Mean (SD).

^§ The alteplase dose was 0.6 mg/kg.

^ǁ Time from the end of idarucizumab injection to intravenous tPA.

^¶ Patients who received only tPA.

^# Patients who received tPA and underwent thrombectomy.